VRCA Stockholder News: Robbins LLP Investigates Verrica Pharmaceuticals Inc. (VRCA) on Behalf of Stockholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) and its officers and directors to determine whether they breached their fiduciary duties and violated securities laws. Verrica is a dermatology therapeutics company that develops medications for viral skin diseases requiring medical intervention.

If you would like more information about our investigation of Verrica Pharmaceuticals Inc.'s misconduct, click here.

What is this Case About: Verrica Pharmaceuticals Inc. (VRCA) Received a Third Complete Response Letter from the FDA relating to its New Drug Application for VP-102

Verrica has spent several years working to bring to market VP-102, the Company's investigational, proprietary, drug-device combination for the treatment of molluscum contagiosum. However, several challenges have prevented this from happening. Verrica received its first Complete Response Letter (CRL) regarding the New Drug Application (NDA) in July 2020 and its second in September 2021. On May 24, 2022, Verrica received yet another CRL from the FDA related to its NDA for VP-102. On this news, the Company's stock price fell 63.85%, to close at $2.01 per share on May 25, 2022.

Next Steps: If you own shares of Verrica Pharmaceuticals Inc. (VRCA), you have legal options. Contact Robbins LLP for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Verrica Pharmaceuticals Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Industry:

Robbins LLP

NASDAQ:VRCA

Release Summary

Verrica Pharmaceuticals Inc. (VRCA) Received a Third Complete Response Letter from the FDA relating to its New Drug Application for VP-102

Release Versions

English

$Cashtags

$VRCA

Hashtags

#VRCA

#VerricaPharmaceuticals

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Social Media Profiles

Robbins LLP

More News From Robbins LLP

Erasca, Inc. Class Action Reminder - Robbins LLP Encourages ERAS Stockholders to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Erasca, Inc. (NASDAQ: ERAS) securities between January 14, 2025 and April 26, 2026. Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

ADMA Biologics, Inc. Stock Drop: Robbins LLP Urges Investors to Contact the Firm for Information About the Class Action Against ADMA Biologics, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. For more information...

VIA Transportation, Inc. Stock Drop: Harmed Investors Should Contact Robbins LLP for Information About Leading the Class Action Against VIA

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Via Transportation, Inc. (NYSE: VIA) in connection with the Company's September 15, 2025 initial public statement ("IPO"). Via Transportation, Inc. provides a platform that transforms global transportation systems into digital networks in the United States, Germany, and internationally.For more information, submit a form, email attorney Aaron D...

Back to Newsroom